Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers
Tachyon Therapeutics, a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets today announced the closing of a financing that brings the Company’s total equity financing raises to $11.6 million and, together with a recently announced CIRM grant of $7.1 million, brings total funding in the Company to $18.7 million since the Company started operations in 2020.
The round includes new investors, Veblen Ventures, Khosla Ventures, and Red Tree Venture Capital, and existing investors, demonstrating their continued commitment to supporting Tachyon’s potential. Proceeds from the financing are being used to run the Phase 1 clinical study in advanced solid tumors for TACH101, a first-in-class, small molecule, KDM4 histone demethylase inhibitor, as well as to advance the Company’s pipeline of emerging oncology drug candidates targeting previously unexplored mechanisms of tumorigenesis.
“The Tachyon team are enabling new frontiers in targeted oncology by developing cancer therapies that address fundamental drivers of tumorigenesis,” commented Heath Lukatch, Ph.D., Managing Director of Red Tree Venture Capital. “We look forward to supporting the team as they work towards transforming the treatment paradigms for advanced and metastatic solid tumors.”
“This new capital, from a committed and distinguished investor syndicate that includes new and existing investors as well as the grant from CIRM, highlights the progress we’ve made to bring our lead program into the clinic,” said Frank Perabo, M.D. Ph.D., Chief Executive Officer of Tachyon.
Founded on the scientific work of Drs. Stephen Quake and Michael Clarke at Stanford University, Tachyon Therapeutics is developing novel, first-in-class therapeutics that target pathways to fight cancer at its core tumorigenic mechanisms. In November 2019, Tachyon received an exclusive license to research, develop, and commercialize products for small molecule inhibitors of KDM4 including TACH101 (formerly QC8222) from Celgene Quanticel Research, Inc, now Bristol Myers Squibb, Summit, NJ. The Company recently received clearance of the Company’s Investigational New Drug (IND) application for TACH101 and enrolled its first patient in a Phase 1 clinical study in patients with advanced or metastatic solid tumors (ClinicalTrials.gov Identifier NCT05076552).
“The start of our first clinical trial for TACH101, our lead program, is a significant milestone for the company as we strive to bring promising new therapeutics to patients who are fighting advanced cancers,” continued Dr. Perabo. “We are also pleased to welcome to our Board of Directors, Dr. Jeff Stafford, who has decades of experience in developing innovative small molecule therapeutics against novel cancer targets and led the initial discovery and development of our novel KDM4-inhibitor, TACH101.”
- Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
- NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
- Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
- Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
- Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more